Glucagonoma syndrome: a review and update on treatment.
John AM, Schwartz RA.
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022. doi: 10.1111/jdv.13752. Epub 2016 Jul 16.
Glucagonoma syndrome.
Bloom SR, Polak JM.
Am J Med. 1987 May 29;82(5B):25-36. doi: 10.1016/0002-9343(87)90424-4.
Glucagonoma syndrome.
van Hecke E, Geerts ML, Kint A, Debersaques J, Naeyaert JM.
Curr Probl Dermatol. 1991;20:24-33. doi: 10.1159/000420005.
Glucagonoma tumors and syndrome.
Montenegro-Rodas F, Samaan NA.
Curr Probl Cancer. 1981 Dec;6(6):1-54. doi: 10.1016/s0147-0272(81)80014-1.
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK.
J Neuroendocrinol. 2023 Aug;35(8):e13318. doi: 10.1111/jne.13318. Epub 2023 Aug 14.
The glucagonoma syndrome.
Wynick D, Hammond PJ, Bloom SR.
Clin Dermatol. 1993 Jan-Mar;11(1):93-7. doi: 10.1016/0738-081x(93)90103-j.
[Glucagonoma syndrome].
Tellechea O, Baptista AP.
Acta Med Port. 1988 Mar-Apr;1(2):149-52.
Glucagonoma syndrome with necrolytic migratory erythema as initial manifestation.
Zhu WF, Zheng SS.
Hepatobiliary Pancreat Dis Int. 2021 Dec;20(6):598-600. doi: 10.1016/j.hbpd.2021.09.005. Epub 2021 Sep 8.
Glucagonoma syndrome with atypical necrolytic migratory erythema.
He S, Zeng W, Geng S, Jia J.
Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):49-53. doi: 10.4103/ijdvl.IJDVL_588_18.
Glucagonoma syndrome.
Adams DR, Miller JJ, Seraphin KE.
J Am Acad Dermatol. 2005 Oct;53(4):690-1. doi: 10.1016/j.jaad.2005.04.071.
